Up 38% in a month, what’s sparking the recent Race Oncology share price run-up?

What a month it has been for Race Oncology shareholders.

| More on:
Five healthcare workers standing together and smiling.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Race Oncology shares have rocketed 39% in the past month, closing up another 15.74% today
  • The company has made a number of positive announcements last month which have helped boost its share price
  • The S&P/ASX 200 Health Care (ASX: XHJ) sector also provided support today, closing almost 2% higher

The Race Oncology Ltd (ASX: RAC) share price had yet another stunning day, leaving the broader index well behind.

At close of trade, the specialty pharmaceutical company’s shares finished 15.74% ahead at $2.50 each. This means the company’s shares have now risen more than 38% in the past month.

For context, the All Ordinaries Index (ASX: XAO) closed 0.5% lower to 6,784.3 points today and is now down more than 9% for the month.

What’s driving Race Oncology shares forward?

Investors were rallying up the Race Oncology share price today amid the company’s latest string of announcements, along with positive sentiment.

Last month, the company advised it was conducting a share buyback to increase shareholder value.

The board approved the purchase of up to four million Race Oncology shares, which represents 2.5% of its issued capital.

When the news broke, this led shares in the company to finish 11.24% higher on the day.

Furthermore, Race Oncology released a statement highlighting two peer-reviewed abstracts published in the scientific journal, Cancer Research.

Both publications noted the company’s new preclinical data on the anti-cancer uses of its lead candidate Zantrene.

Again, when Race Oncology provided the update to the ASX, its shares soared 10% before market close.

After that, there was another rush on the company’s shares following successful results from its Zantrene trial.

The clinical data showed that the anti-cancer drug protected the hearts of mice from chemotherapy damage.

This is particularly significant as the company is seeking to capture the “large commercial opportunity” that’s present for Zantrene.

Lastly, helping the accent of Race Oncology shares is the S&P/ASX 200 Health Care (ASX: XHJ) sector advancing 1.97% today.

About the Race Oncology share price

Despite the strong gains made over the month, the Race Oncology share price is down 30% in 2022.

This is due to extreme market volatility impacting ASX shares amid rampant inflation, interest rate hikes, and a downbeat economic outlook.

Based on today’s price, Race commands a market capitalisation of around $398 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Why this broker sees plenty of upside for the ResMed share price

ResMed shares could be in the buy zone...

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

Looking to buy CSL shares? Here’s what to watch when the biotech company reports this week

Here’s what might be around the corner for CSL this earnings season.

Read more »

A scientist examining test results.
Healthcare Shares

Why did the Opthea share price dive 9% on Monday?

The biopharmaceutical company has announced new share issue arrangements.

Read more »

A disappointed female investor sits in front of her laptop and puts her hand to her forehead and closes her eyes in disappointment over share price falls
Capital Raising

Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise

Paradigm shares have erased all of last week's gains...

Read more »

A woman stands facing a set of shelves that is completely empty.
Healthcare Shares

The ASX 200 company selling everything it makes due to its major competitor being out of the market: fundie

ResMed is performing strongly right now.

Read more »

a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.
Healthcare Shares

Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

Read more »

A sad looking scientist sitting and upset about a share price fall.
Earnings Results

Avita share price dives 16% on net loss

The medical technology company's shares are falling following today's financial results

Read more »

A man waking up happy with a smile on his face and arms outstretched representing the hefty Adairs dividend yield
Earnings Results

ResMed share price on watch following solid FY22 growth

ResMed has released its full year results...

Read more »